Luye Pharma Group 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dian Bo Liu

최고 경영자

CN¥4.2m

총 보상

CEO 급여 비율	75.1%
CEO 임기	21.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	12.8yrs
이사회 평균 재임 기간	10.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dian Bo Liu 의 보수는 Luye Pharma Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥770m
Mar 31 2024	n/a	n/a	CN¥652m
Dec 31 2023	CN¥4m	CN¥3m	CN¥533m
Sep 30 2023	n/a	n/a	CN¥495m
Jun 30 2023	n/a	n/a	CN¥458m
Mar 31 2023	n/a	n/a	CN¥531m
Dec 31 2022	CN¥3m	CN¥3m	CN¥605m
Sep 30 2022	n/a	n/a	CN¥190m
Jun 30 2022	n/a	n/a	-CN¥224m
Mar 31 2022	n/a	n/a	-CN¥179m
Dec 31 2021	CN¥4m	CN¥3m	-CN¥134m
Sep 30 2021	n/a	n/a	CN¥210m
Jun 30 2021	n/a	n/a	CN¥554m
Mar 31 2021	n/a	n/a	CN¥630m
Dec 31 2020	CN¥5m	CN¥4m	CN¥707m
Sep 30 2020	n/a	n/a	CN¥955m
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥4m	CN¥3m	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥4m	CN¥3m	CN¥981m

보상 대 시장: Dian Bo 의 총 보상 ($USD 576.71K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 487.93K ).

보상과 수익: Dian Bo 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Dian Bo Liu (58 yo)

21.3yrs

테뉴어

CN¥4,180,000

보상

Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dian Bo Liu	Co-Founder	21.3yrs	CN¥4.18m	데이터 없음
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.3yrs	CN¥3.09m	데이터 없음
Hui Xian Yuan	Co-Founder & Executive Director	no data	CN¥1.46m	데이터 없음
Yuan Yuan Zhu	Executive Director	no data	CN¥1.50m	데이터 없음
Yuan Chong Liu	Chief Financial Officer	12.8yrs	데이터 없음	데이터 없음
Mei Yi Lee	Company Secretary	3.9yrs	데이터 없음	데이터 없음

12.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 2186 의 관리팀은 노련하고 경험 (평균 재직 기간 12.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dian Bo Liu	Co-Founder	21.3yrs	CN¥4.18m	데이터 없음
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.3yrs	CN¥3.09m	데이터 없음
Hui Xian Yuan	Co-Founder & Executive Director	21.3yrs	CN¥1.46m	데이터 없음
Yuan Yuan Zhu	Executive Director	10.7yrs	CN¥1.50m	데이터 없음
Yuk Lam Lo	Independent Non-Executive Director	10.4yrs	CN¥269.00k	데이터 없음
Man Kit Leung	Independent Non-Executive Director	10.4yrs	CN¥322.00k	데이터 없음
Rui Lin Song	Non-Executive Director	7.7yrs	CN¥269.00k	데이터 없음
Sze Chung Choy	Independent Non-Executive Director	10.4yrs	CN¥269.00k	데이터 없음
Huaqiao Zhang	Independent Non-Executive Director	10.4yrs	CN¥269.00k	데이터 없음
Dong Lyu	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Lian Xia	Independent Non-Executive Director	1.5yrs	CN¥162.00k	데이터 없음

10.4yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 2186 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.4 년).

Luye Pharma Group 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Less than half of directors are independent

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Less than half of directors are independent

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in FY 2022)

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Investor sentiment improves as stock rises 16%

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.039 loss in FY 2021)

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection

Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States

Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)

Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in China

Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United Kingdom

Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015

Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.S

Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in China

Investor sentiment improved over the past week